7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An effective HIV vaccine will likely need to induce broad and potent CTL responses. Epitope-based vaccines offer significant potential for inducing multi-specific CTL, but often require conjugation to T helper epitopes or carrier moieties to induce significant responses. We tested hybrid DNA vaccines encoding one or more HIV or SIV CTL epitopes fused to a hepatitis B core antigen (HBcAg) carrier gene as a means to improve the immunogenicity of epitope-based DNA vaccines. Immunization of mice with a HBcAg-HIV epitope DNA vaccine induced CD8+ T cell responses that significantly exceeded levels induced with DNA encoding either the whole HIV antigen or the epitope alone. In rhesus macaques, a multi-epitope hybrid HBcAg-SIV DNA vaccine induced CTL responses in rhesus macaques to 13 different epitopes, including 3 epitopes that were previously not detected in SIV-infected macaques. These data demonstrate that immunization with hybrid HBcAg-epitope DNA vaccines is an effective strategy to increase the magnitude and breadth of HIV-specific CTL responses.

          Related collections

          Author and article information

          Journal
          0110674
          8015
          Virology
          Virology
          Virology
          0042-6822
          1096-0341
          30 April 2009
          11 April 2007
          01 August 2007
          08 December 2018
          : 364
          : 2
          : 245-255
          Affiliations
          [1 ] PowderJect Vaccines, Inc., Madison, WI, 53562
          [2 ] Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53715
          [3 ] Wisconsin Regional Primate Research Center, Madison, WI, 53715
          Author notes
          [* ]Corresponding Author: Deborah H. Fuller, Department of Molecular Genetics and Biochemistry, University of Pittsburgh, School of Medicine, RIDC Park, 260 Kappa Drive, Pittsburgh, PA 15238, Ph: 412-967-6505; Fax: 412-967-6568, Email: dfuller@ 123456pitt.edu
          [4]

          Department of Molecular Genetics and Biochemistry, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15238

          [5]

          Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129

          [6]

          Recombiworks, Cranberry, PA, 16066

          [7]

          Fred Hutchinson Cancer Research Center, Seattle, WA 98109

          [8]

          ALZA Corporation, Drug-Device Research, Mountain View, CA 94039-7210

          Article
          PMC6286304 PMC6286304 6286304 nihpa25780
          10.1016/j.virol.2007.02.024
          6286304
          17428516
          8d5f21dd-a32c-4aa9-8ada-461e31582b01
          History
          Categories
          Article

          Comments

          Comment on this article